Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat lower versus standard starting dose in non-dialysis CKD anemia
ChiCTR2100045359Phase 4Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of roxadustat in Uraemic Anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Mean change in hemoglobin from baseline to the average over weeks 12-16. Started Oct 2020; status: completed.
02
Drugs
roxadustat
03
Conditions
Uraemic Anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2100045359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045359.